Earnings
Charlotte's Web Reports 2025 Fourth Quarter and Full Year Financial Results
BAT Debt Swap and Medicare Pilot Buy Time as Cash Burn Persists

Executive Summary
- Charlotte's Web reported Q4 2025 revenue of $13.3M (+4.7% YoY) and full-year 2025 revenue of $49.9M (+0.5% YoY), marking the first annual revenue increase since 2021.
- The company posted a Q4 net loss of $11.5M and a full-year net loss of $29.7M, with adjusted EBITDA of -$4.4M for Q4 and -$12.9M for FY2025.
- Cash and cash equivalents fell sharply to $8.0M from $22.6M, leaving the company with a shareholder equity deficit of $(2.0)M.
- A definitive transaction with BAT DE Investments was announced: conversion of a C$75.3M convertible debenture plus accrued interest, alongside a US$10M private placement equity investment at C$0.94 per share.
- Post-transaction, BAT will hold approximately 40% of outstanding common shares, eliminating the company's largest debt liability and halting ~US$12M in future interest expenses.
- Proceeds are earmarked for the CMMI Medicare pilot program launch (effective April 1, 2026) and continued funding of the DeFloria AJA001 Phase 2 clinical trial for autism spectrum disorder.
- The transaction requires TSX and shareholder approval, targeted for the AGM/Special Meeting around May 28, 2026.
Material Impact
- The BAT transaction is structurally transformative, removing an existential debt overhang and injecting immediate liquidity into a critically thin balance sheet.
- The 40% equity stake granted to BAT represents severe dilution for existing shareholders, fundamentally altering the capital structure and shifting control dynamics.
- Financial results confirm management's cost-cutting narrative (SG&A down YoY, manufacturing internalization progressing), but top-line growth remains anemic and cash burn persists.
- The CMMI Medicare pilot provides a tangible, federally backed commercial catalyst, but initial revenue contribution is unproven and dependent on complex reimbursement mechanics.
- Overall, the news resolves near-term solvency risk and validates the strategic pivot toward medical and pharmaceutical channels, but execution risk and dilution cap immediate upside.
CWEB · Price
Company Overview
- Charlotte's Web is a U.S.-based botanical wellness company specializing in hemp-derived CBD, low-dose Delta-9 THC, and functional mushroom products.
- Flagship Project: The Brightside line of precision-formulated, fast-acting hemp-derived THC gummies utilizing proprietary TiME INFUSION technology. This line targets the rapidly growing hemp-THC wellness segment and is now ~75% produced in-house to improve margins.
- Secondary Initiatives: Expansion into functional mushroom sleep aids, omnichannel digital distribution (Amazon, TikTok Shop, Faire), and the DeFloria joint venture developing AJA001 for autism-related irritability.
More from CHARLOTTE'S WEB HOLDINGS, INC.
Jun 26, 2026 · 07:22